Sections
| Title | Starting Page | Number of Pages |
|---|
| GBIHC018MR - Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma | 1 | 89 |
| 1 Table of Contents | 3 | 5 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 7 | 1 |
| 2 RNA Therapeutics: Introduction | 8 | 1 |
| 2.1 GBI Research Report Guidance | 8 | 1 |
| 3 RNA Therapeutics Introduction to Ribonucleic Acid (RNA) | 9 | 3 |
| 3.1 What is RNA Therapy? | 9 | 1 |
| 3.1.1 RNA is the Key for Protein Synthesis | 9 | 1 |
| 3.1.1.1 Amino Acid Synthesis | 9 | 1 |
| 3.1.1.2 Transcription | 9 | 1 |
| 3.1.1.3 Translation | 9 | 1 |
| Blocking Translation of mRNA Inhibits Protein Biosynthesis, the Key for Cell Proliferation | 10 | 1 |
| 3.3 Role of RNA in Pharmaceutical Industry | 10 | 1 |
| 3.3.1 Upstream Action of RNA Therapies Make them more effective Than the Existing Biologic Therapies | 10 | 1 |
| 3.3.1.1 Upstream Mechanism of Action | 11 | 1 |
| 3.3.1.2 Potential to act through natural pathway | 11 | 1 |
| 3.3.1.3 Potential to Target any Protein | 11 | 1 |
| 3.3.1.4 Reduced Time for Developing Therapies | 11 | 1 |
| 4 RNA Therapeutics Overview on RNA Technology | 12 | 12 |
| 4.1 Antisense RNA | 12 | 1 |
| 4.1.1 Therapeutic Objective | 12 | 1 |
| 4.1.2 Issues with Antisense RNA Therapy | 12 | 1 |
| 4.1.2.1 Antisense RNA Therapies Are Susceptible to Nuclease Enzymes That Are Present Through Out the Body | 12 | 1 |
| Naked Antisense RNA Therapies Have Poor Penetration Rates and Therefore, Fail to Display Desired Efficacy Levels | 13 | 1 |
| 4.1.2.3 Effective Delivery Systems That Can Mask Antisense RNA Therapies and Deliver Them to the Site of Action Are the Key | 13 | 1 |
| Solutions Developed to Overcome Issues | 14 | 1 |
| 4.1.3.1 New Drug Delivery Technologies Are Being Adopted to Effectively Delivery Antisense RNA Therapies at the Desired Cell | 14 | 1 |
| 4.1.3.2 Synthetic Antisense Oligonucleotides Are Resistant to RNA Nucleases and They Display Better Efficacy Results than Normal Antisense Oligonucleotides | 14 | 1 |
| 4.2 RNA Interference Technology | 15 | 1 |
| 4.2.1 siRNA | 15 | 1 |
| 4.2.1.1 Therapeutic Objective | 15 | 1 |
| 4.2.2 Micro RNA | 16 | 1 |
| 4.2.2.1 Therapeutic Objective | 16 | 1 |
| 4.2.3 Issues with Interfering RNA Therapy | 17 | 1 |
| 4.2.3.1 Similar to Antisense RNA Therapies, Naked siRNA Therapies Too Are Vulnerable to Serum Nucleases | 17 | 1 |
| 4.2.3.2 RNA Interference Therapies Sometimes Activate Interferon Responses | 18 | 1 |
| 4.2.3.3 The Degradation by Serum Nucleases and Lack of Effective Delivery Systems Are Restraining RNAi Therapies from Proving Their Efficacy and Safety Profiles | 18 | 1 |
| 4.2.4 Soultions Developed to Overcome Issues | 19 | 1 |
| 4.2.4.1 Redesigning is One of the successful means to Develop Therapies That Can Effectively induce Gene Suppression through RNA interference Pathway | 19 | 1 |
| 4.2.4.2 Drug Delivery Technologies, Both Viral and Non-viral, That Can Deliver RNAi Therapies at The site of Action Are in Requirement | 19 | 2 |
| 4.2.4.3 Modifications to RNAi Therapies Can Enhance Stability and Half-life, and Reduce Off-target Effects | 21 | 1 |
| 4.2.4.4 Synthetic siRNAs Are Resistant to Degradation by Serum Nucleases | 21 | 1 |
| 4.3 RNA Therapies Are Expected To Create Significant Impact on the Current Therapies After They Enter the Market | 22 | 1 |
| 4.3.1 Current Therapies in the Market Are Expected to Witness Strong Competition from RNA Therapies Once They Enter the Market | 22 | 1 |
| 4.3.2 RNA Therapies Have Created a Significant Impact on Major Funding Institutions Such As Venture Capitalist Firms and Private Equity Firms | 22 | 1 |
| 4.3.3 The Impact of RNA Therapies on Patients Is Expected To Grow Gradually Since Patients Would Switch Over Only After RNA Therapies Pass through Proof-Of-Concept Studies | 22 | 1 |
| RNA Therapeutics Has Already Made a Significant Impact on Large Pharmaceutical and Biotech Companies | 23 | 1 |
| 4.4 Key Challenges Such As Lack of Effective Delivery Systems are Holding Back RNA Therapies from Entering the Market | 23 | 1 |
| 5 RNA Therapeutics Market Characterization | 24 | 8 |
| 5.1 Market Potential | 24 | 1 |
| Target Sales Volume | 25 | 1 |
| 5.3 Annual Cost of Therapy | 26 | 1 |
| Technology Adoption Framework | 27 | 1 |
| 5.4.1 RNA Technology has the potential to meet Unmet-needs in Major Diseases | 27 | 1 |
| 5.4.1.1 Cancer | 27 | 1 |
| 5.4.1.2 Viral Infections | 27 | 1 |
| 5.4.2 RNA technology Failed in Proof-of-concept Studies | 27 | 1 |
| 5.4.3 Lack of awareness among patients as well as physicians is embracing the adoption of RNA Technology | 28 | 1 |
| 5.4.4 RNA therapies, launched till now, failed to pass through proof-of-concept studies | 28 | 1 |
| 5.5 RNA Therapeutics Market Drivers | 28 | 1 |
| 5.5.1 Dual Mechanism of Action is the Major Factor Driving RNA Therapeutics Market Potential | 28 | 1 |
| 5.5.2 Failure of Conventional Therapies in Curing Chronic Diseases has Created High-unmet Needs | 29 | 1 |
| Major Break-through Technologies in RNA Research and Development Opened-up New Markets | 30 | 1 |
| 5.5.4 Increased Funding on RNA Research by Major Countries such as the US and Europe | 30 | 1 |
| 5.6 RNA Therapeutics Market Restraints | 30 | 1 |
| 5.6.1 Many RNA Therapies are Failing at Phase III Clinical Development | 30 | 1 |
| 5.6.2 The Characteristics of RNA Structure make them Vulnerable to Human Enzymes | 31 | 1 |
| 5.6.3 Lack of Effective Delivery Technologies That can Deliver RNA therapies to the Target Site are making RNA Therapies Ineffective | 31 | 1 |
| 5.6.4 RNA therapies can cause potential side-effects and off-target effects | 31 | 1 |
| 6 RNA Therapeutics Market Description | 32 | 8 |
| SWOT Analysis | 32 | 1 |
| 6.1.1 RNA Therapies Hold a Competitive Edge over Conventional Therapies Due to Their Gene Silencing Ability | 32 | 1 |
| 6.1.2 Although RNA Therapies Have the Potential to Cure Diseases, Few Drawbacks Such As Instability and Off-targets are Holding Them from Displaying Desired Efficacy Levels | 32 | 1 |
| 6.1.3 Abundant Opportunities in Terms of Unmet Needs Exist for RNA Therapies in Chronic disease Conditions Associated with Genetic Mutations and Protein Overexpression | 33 | 1 |
| 6.1.4 Similar to RNA Therapies, Other Treatments such as Stem Cell Therapies Are Also in Research and Development, and These Therapies Can Pose a Threat to RNA Therapeutics Market Potential | 33 | 1 |
| 6.2 Porters Five Forces Analysis on RNA Therapeutics | 33 | 1 |
| 6.2.1 Threat of Substitutes | 33 | 1 |
| 6.2.2 Threat of Potential Entrants | 34 | 1 |
| 6.2.3 Bargaining Power of Suppliers | 34 | 1 |
| 6.2.4 Bargaining Power of Buyers | 34 | 1 |
| PEST Analysis | 35 | 1 |
| 6.3.1 The US | 35 | 1 |
| 6.3.1.1 Political Forces | 35 | 1 |
| 6.3.1.2 Economic Factors | 35 | 1 |
| Technical Forces | 36 | 1 |
| 6.3.1.4 Social Forces | 36 | 1 |
| 6.3.2 The Top five Countries in Europe | 36 | 1 |
| 6.3.2.1 Political Forces | 36 | 1 |
| 6.3.2.2 Economic Factors | 37 | 1 |
| 6.3.2.3 Technical Forces | 37 | 1 |
| 6.3.2.4 Social Forces | 37 | 1 |
| 6.3.3 Japan | 37 | 1 |
| 6.3.3.1 Political Forces | 38 | 1 |
| 6.3.3.2 Economic Factors | 38 | 1 |
| 6.3.3.3 Technical Forces | 38 | 1 |
| 6.3.3.4 Social Forces | 38 | 1 |
| 6.4 Funding | 38 | 1 |
| 6.4.1 US | 38 | 1 |
| 6.4.2 Europe | 39 | 1 |
| 7 RNA Therapeutics Competitive Landscape | 40 | 16 |
| 7.1 Key Players | 41 | 1 |
| 7.1.1 Antisense Pharma GmbH | 41 | 1 |
| 7.1.1.1 Trabedersen | 41 | 1 |
| 7.1.1.2 AP11014 | 42 | 1 |
| 7.1.2 Lorus Therapeutics | 42 | 1 |
| 7.1.2.1 LOR-2040 | 42 | 1 |
| 7.1.3 Isis Pharmaceuticals | 43 | 1 |
| 7.1.3.1 Mipomersen | 43 | 1 |
| 7.1.3.2 Vitravene | 43 | 1 |
| 7.1.4 Alfacell Corporation | 44 | 1 |
| 7.1.4.1 Onconase | 44 | 1 |
| 7.1.5 Genta Incorporated | 45 | 1 |
| 7.1.5.1 Genasense | 45 | 1 |
| Atlantic Healthcare | 46 | 1 |
| 7.1.6.1 Alicaforsen | 46 | 1 |
| 7.1.7 Alnylam | 46 | 1 |
| 7.1.8 OPKO | 50 | 1 |
| Bevasiranib | 51 | 1 |
| 7.2 Promising Companies Developing RNAi under Collaborations with major Companies | 51 | 1 |
| 7.2.1 Oxford BioMedica | 51 | 2 |
| 7.2.2 Dicerna Pharmaceuticals | 53 | 1 |
| 7.2.3 Silence Therapeutics plc | 53 | 1 |
| 7.2.4 Cequent Pharmaceuticals, Inc | 54 | 1 |
| 7.2.5 SantarisPharma A/S | 54 | 2 |
| 8 RNA Therapeutics R&D Pipeline Analysis | 56 | 14 |
| 8.1 Strategic Pipeline Assessment | 56 | 3 |
| 8.2 Profiles of Key Late-Stage Drugs | 59 | 1 |
| 8.2.1 Mipomersen | 59 | 1 |
| 8.2.1.1 Follow on Indications | 59 | 1 |
| 8.2.2 Bevasiranib | 59 | 1 |
| Follow On indication | 60 | 1 |
| 8.2.3 LOR-2040 | 60 | 1 |
| 8.2.3.1 Mechanism of Action | 60 | 1 |
| 8.2.3.2 Follow on Indication | 60 | 1 |
| 8.2.4 Genasense | 60 | 1 |
| 8.2.4.1 Mechanism of Action | 61 | 1 |
| 8.2.4.2 Follow on Indication | 61 | 1 |
| 8.2.5 Trovax | 61 | 1 |
| 8.2.5.1 Mechanism of Action | 61 | 1 |
| 8.2.5.2 Follow on Indications | 61 | 1 |
| 8.2.6 Trabedersen | 61 | 1 |
| 8.2.6.1 Mechanism of Action | 61 | 1 |
| 8.2.6.2 Follow on Indications | 61 | 1 |
| Onconase | 62 | 1 |
| 8.2.7.1 Mechanism of Action | 62 | 1 |
| 8.2.7.2 Follow on Indications | 62 | 1 |
| 8.2.8 Alicaforsen | 62 | 1 |
| 8.2.8.1 Mechanism of Action | 62 | 1 |
| 8.2.8.2 Follow on Indication | 62 | 1 |
| 8.3 Insights into Most Promising Drugs | 63 | 1 |
| 8.3.1 Mipomersen | 63 | 1 |
| 8.3.1.1 Follow on Indications | 63 | 1 |
| 8.3.1.2 Clinical Studies | 63 | 1 |
| 8.3.2 LOR-2040 | 63 | 1 |
| Mechanism of Action | 64 | 1 |
| 8.3.2.2 Follow on Indication | 64 | 1 |
| 8.3.2.3 Clinical Studies | 64 | 1 |
| 8.3.3 Genasense | 64 | 1 |
| 8.3.3.1 Mechanism of Actions | 65 | 1 |
| 8.3.3.2 Follow on Indication | 65 | 1 |
| 8.3.3.3 Clinical Studies | 65 | 1 |
| 8.3.4 ProSavin | 65 | 1 |
| 8.3.4.1 Clinical Studies | 65 | 1 |
| Trovax | 66 | 1 |
| 8.3.5.1 Mechanism of Action | 66 | 1 |
| 8.3.5.2 Follow on Indication | 66 | 1 |
| 8.3.5.3 Clinical Studies | 66 | 1 |
| 8.3.6 Trabedersen | 66 | 1 |
| 8.3.6.1 Mechanism of Action | 67 | 1 |
| 8.3.6.2 Follow on Indications | 67 | 1 |
| 8.3.6.3 Clinical Studies | 67 | 1 |
| 8.3.7 Onconase | 67 | 1 |
| 8.3.7.1 Mechanism of Action | 67 | 1 |
| 8.3.7.2 Follow on Indications | 68 | 1 |
| 8.3.7.3 Clinical Studies | 68 | 1 |
| 8.3.8 Alicaforsen | 68 | 1 |
| 8.3.8.1 Mechanism of Action | 68 | 1 |
| 8.3.8.2 Follow on Indication | 68 | 1 |
| 8.3.8.3 Clinical Studies | 69 | 1 |
| RNA Therapeutics M&A Landscape | 70 | 13 |
| 9.1 Big Pharmaceutical Companies Relentlessly Attempting to Unlock RNA therapy Potential | 70 | 1 |
| Influx of Huge Venture Capitalist Funding into Small and Medium Biotech Companies Venturing into RNA Therapeutics Development | 71 | 1 |
| 9.2.1 Dicerna Pharmaceuticals | 71 | 1 |
| 9.2.2 Cequent Pharmaceuticals | 71 | 1 |
| 9.2.3 Prosensa | 71 | 1 |
| 9.2.4 Cylene Pharmaceuticals | 71 | 1 |
| 9.3 High Value Collaborations involving RNA Therapies | 71 | 1 |
| 9.3.1 ISIS Pharmaceuticals | 71 | 1 |
| 9.3.2 Alnylam | 72 | 1 |
| 9.3.3 Silence Therapeutics and AstraZeneca | 72 | 1 |
| 9.3.4 Santaris Pharma and Wyeth Pharmaceuticals | 72 | 1 |
| 9.4 Large Pharmaceutical and Biotechnology companies are vying for major acquisitions in the RNA Therapeutics Market | 72 | 1 |
| 9.4.1 Thermo Fisher Scientific and Open Biosystems | 72 | 1 |
| 9.4.2 Roche and Mirus Bio | 72 | 1 |
| R&D Licensing Agreements | 73 | 1 |
| 9.5.1 Deals by Phase | 73 | 1 |
| 9.5.2 Deals by Geography | 73 | 1 |
| 9.5.3 Deals by Licensing Type | 74 | 1 |
| 9.5.4 Deals by Value ($) | 75 | 1 |
| 9.5.5 Discovery/Development | 75 | 1 |
| 9.5.5.1 GlaxoSmithKline (GSK) and Prosensa Alliance Worth $680 million | 75 | 1 |
| 9.5.5.2 Alnylam Pharmaceuticals, Inc. with Isis Pharmaceuticals, Inc | 75 | 1 |
| Alnylam Pharmaceuticals, Inc with Takeda Pharmaceutical Company Limited | 76 | 1 |
| 9.5.5.4 Alnylam Pharmaceuticals, Inc with GlaxoSmithKline (GSK) | 76 | 1 |
| 9.5.5.5 Archemix Corporation with Eli Lilly and Company | 76 | 1 |
| 9.5.5.6 Archemix Corporation with GlaxosmithKline (GSK) | 76 | 1 |
| 9.5.5.7 PTC Therapeutics with Roche | 76 | 1 |
| 9.5.5.8 PTC Therapeutics with Schering-Plough Corporation | 77 | 1 |
| 9.5.5.9 Santaris Pharma A/S with Shire plc | 77 | 1 |
| 9.5.5.10 Tekmira with Roche | 77 | 1 |
| 9.5.5.11 Tekmira with Bristol-Myers Squibb Company | 77 | 3 |
| 9.5.6 Preclinical | 80 | 1 |
| 9.5.6.1 Novosom AG with Isis Pharmaceuticals: | 80 | 1 |
| 9.5.7 Phase I | 81 | 1 |
| 9.5.8 Phase II | 81 | 1 |
| 9.5.8.1 Cubist Pharmaceuticals, Inc. with Alnylam Pharmaceuticals, Inc: | 81 | 1 |
| 9.5.9 Phase III | 82 | 1 |
| 9.5.9.1 Alfacell Corporation with Strativa Pharmaceuticals | 82 | 1 |
| 10 RNA Therapeutics: Appendix | 83 | 7 |
| 10.1 Market Definitions | 83 | 1 |
| 10.2 Abbreviations | 83 | 1 |
| 10.3 Research Methodology | 84 | 5 |
| 10.3.1 Coverage | 85 | 1 |
| 10.3.2 Secondary Research | 85 | 1 |
| 10.3.3 Primary Research | 86 | 1 |
| 10.3.4 Forecasts | 86 | 1 |
| 10.3.4.1 Epidemiology-based Forecasting | 86 | 2 |
| 10.3.5 Expert Panel Validation | 88 | 1 |
| 10.4 Contact Us | 89 | 1 |
| 10.5 Disclaimer | 89 | 1 |
| 10.6 Sources | 89 | 1 |